BioXcel Therapeutics Inc
BTAI2.125USD
+0.755+55.11%
交易中 （美东）报价延迟15分钟
11.62M总市值
亏损市盈率 TTM
关于 BioXcel Therapeutics Inc 公司
BioXcel Therapeutics, Inc. 是一家利用人工智能开发神经科学药物的生物制药公司。其子公司 OnkosXcel Therapeutics 开发免疫肿瘤学药物。该公司最先进的神经科学候选药物 BXCL501 是一种研究性、专有的口服溶解膜制剂 Dex，正在开发中，用于治疗与精神和神经系统疾病相关的躁动。该公司正在继续开发 BXCL501，用于在家中对与双相情感障碍或精神分裂症相关的躁动进行潜在的急性治疗，以及用于在家中和护理机构中对可能因阿尔茨海默病导致的痴呆症相关的躁动（非日常）进行潜在的急性治疗。其最先进的免疫肿瘤学候选药物 BXCL701 是一种研究性口服先天免疫激活剂，用于治疗侵袭性前列腺癌、胰腺癌以及其他实体和液体肿瘤。
公司简介
公司代码BTAI
公司名称BioXcel Therapeutics Inc
上市日期Mar 08, 2018
CEODr. Vimal Mehta, Ph.D.
员工数量37
证券类型Ordinary Share
年结日Mar 08
公司地址555 Long Wharf Dr
城市NEW HAVEN
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编06511-6107
电话12036438060
网址https://www.bioxceltherapeutics.com/
公司代码BTAI
上市日期Mar 08, 2018
CEODr. Vimal Mehta, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
19.80K
+373.89%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
18.62K
+10.00%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.66K
+301.39%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.44K
+346.98%
Mr. Erik Kopp
Mr. Erik Kopp
Investor Relations
Investor Relations
--
--
DR. Frank D. Yocca ,Ph.D.
DR. Frank D. Yocca ,Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Dr. Rajiv Patni, M.D.
Dr. Rajiv Patni, M.D.
Independent Director
Independent Director
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
19.80K
+373.89%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
18.62K
+10.00%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.66K
+301.39%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.44K
+346.98%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月24日 周四
更新时间: 7月24日 周四
持股股东
股东类型
持股股东
持股股东
占比
Bioxcel Corp
7.93%
Armistice Capital LLC
4.76%
Murchinson Ltd.
2.25%
UBS Financial Services, Inc.
1.68%
Goldman Sachs & Company, Inc.
0.41%
Other
82.97%
持股股东
持股股东
占比
Bioxcel Corp
7.93%
Armistice Capital LLC
4.76%
Murchinson Ltd.
2.25%
UBS Financial Services, Inc.
1.68%
Goldman Sachs & Company, Inc.
0.41%
Other
82.97%
股东类型
持股股东
占比
Corporation
7.93%
Hedge Fund
4.76%
Investment Advisor
2.76%
Investment Advisor/Hedge Fund
2.62%
Individual Investor
1.28%
Research Firm
0.89%
Other
79.75%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
225
1.20M
19.77%
-199.41K
2025Q1
248
1.19M
19.87%
-219.94K
2024Q4
260
1.00M
33.25%
-269.93K
2024Q3
269
724.21K
25.25%
-802.39K
2024Q2
282
1.14M
44.29%
-598.60K
2024Q1
282
1.17M
59.63%
-354.60K
2023Q4
282
1.17M
63.22%
-360.50K
2023Q3
290
1.23M
67.44%
-639.74K
2023Q2
289
1.71M
93.56%
-204.68K
2023Q1
297
1.69M
93.06%
-56.17K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Bioxcel Corp
480.34K
7.93%
-53.83K
-10.08%
Jun 06, 2024
Armistice Capital LLC
288.13K
4.76%
-24.20K
-7.75%
Mar 31, 2025
Murchinson Ltd.
136.08K
2.25%
+136.08K
--
Mar 31, 2025
UBS Financial Services, Inc.
101.78K
1.68%
+21.97K
+27.53%
Mar 31, 2025
Goldman Sachs & Company, Inc.
24.79K
0.41%
+24.79K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
22.87K
0.38%
-508.00
-2.17%
Mar 31, 2025
Geode Capital Management, L.L.C.
22.06K
0.36%
+2.56K
+13.15%
Mar 31, 2025
Mehta (Vimal)
4.18K
0.07%
+382.00
+10.06%
Jun 15, 2025
Beacon Pointe Advisors LLC
18.84K
0.31%
+18.84K
--
Mar 31, 2025
The Vanguard Group, Inc.
18.82K
0.31%
+18.82K
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Neuroscience and Healthcare ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Broad Market ETF
0%
iShares Micro-Cap ETF
0%
iShares Morningstar Small-Cap ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
WisdomTree Artificial Intelligence and Innov Fund
0%
查看更多
ProShares Hedge Replication ETF
占比0%
Schwab U.S. Small-Cap ETF
占比0%
iShares Neuroscience and Healthcare ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Schwab U.S. Broad Market ETF
占比0%
iShares Micro-Cap ETF
占比0%
iShares Morningstar Small-Cap ETF
占比0%
Fidelity MSCI Health Care Index ETF
占比0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0%
WisdomTree Artificial Intelligence and Innov Fund
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
公告日期
类型
比率
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
